263365-58-8

Upstream product

• 29311-53-3 (E)-3-hexene-1,6-dioic acid 
• 25126-93-6 dimethyl trans-3-hexene-1,6-dioate 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 71655-17-9 (E)-3-hexen-1,6-diol 
• 927670-17-5 6-(tert-butyldiphenylsilanyloxy)hex-3-en-1-ol 

Downstream Products

• 263365-64-6 N'-[8-(tert-butyl-diphenyl-silanyloxy)-oct-5-enylidene]-N,N-dimethyl-hydrazine 
• 263365-59-9 tert-Butyl-[((E)-nona-3,8-dienyl)oxy]-diphenyl-silane 
• 263365-61-3 tert-butyl-(12-chloro-dodec-3-enyloxy)-diphenyl-silane 
• 1007313-81-6 C₂₃H₂₉NOSi 
• 939054-89-4 (5E)-8-(tert-butyldiphenylsilanyloxy)-2-(diethoxyphosphoryl)oct-5-enoic acid methyl ester 
• 939054-94-1 (5E)-8-(tert-butyldiphenylsilanyloxy)-2-((2R,E)-1-tritylaziridin-2-ylmethylene)oct-5-enoic acid methyl ester 
• 939054-95-2 (5E)-2-((2R,E)-aziridin-2-ylmethylene)-8-(tert-butyldiphenylsilanyloxy)oct-5-enoic acid methyl ester 
• 939054-96-3 (5E)-2-((2R,E)-1-acetylaziridin-2-ylmethylene)-8-(tert-butyldiphenylsilanyloxy)oct-5-enoic acid methyl ester 
• 939054-90-7 (4R)-4-[(3E)-6-(tert-butyldiphenylsilanyloxy)hex-3-enyl]-2-oxo-2,3,4,7-tetrahydro-1H-azepine-4-carboxylic acid methyl ester 
• 939054-97-4 C₃₆H₄₂N₂O₈SSi 
• 939054-91-8 (2R)-2-[(3E)-6-(tert-butyldiphenylsilanyloxy)hex-3-enyl]-2-[(Z)-3-(4-nitrobenzenesulfonyamino)prop-1-enyl]succinic acid dimethyl ester 
• 939054-98-5 C₃₆H₄₂N₂O₈SSi 
• 939054-92-9 {(3R)-3-[(3E)-6-(tert-butyldiphenylsilanyloxy)hex-3-enyl]-2-oxo-1,2,3,6-tetrahydropyridin-3-yl}acetic acid methyl ester 
• 939054-88-3 2-{(3R)-3-[(3E)-6-(tert-butyldiphenylsilanyloxy)hex-3-enyl]-2-oxo-1,2,3,6-tetrahydropyridin-3-yl}-N-(3,4-dimethoxyphenyl)acetamide 

Relevant academic research and scientific papers

Preparation of 3-alkylpyridines. Formal total synthesis of haliclamines A and B

The formal total synthesis of two sponge alkaloids Haliclamines A and B is achieved through the preparation of 3-alkylpyridines 3, 4 and 5 via an advanced common intermediate 6. (C) 2000 Elsevier Science Ltd.

Synthesis of pochoxime prodrugs as potent HSP90 inhibitors

Pochoximes are potent inhibitors of heat shock protein 90 (HSP90) based on the radicicol pharmacophores. Herein we present a pharmacokinetics and pharmacodynamics evaluation of this compound series as well as a phosphate prodrug strategy to facilitate for

MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90

Disclosed are macrocyclic compounds of formulae I-V,which are analogs of the pochonin resorcylic acid lactones, and processes for the preparation of the compounds. The compounds disclosed are useful as inhibitors of kinases and Heat Shock Protein 90 (HSP 90). Also disclosed are pharmaceutical compositions comprising an effective kinase-inhibiting amount or an effective HSP90-inhibiting amount of the compounds and methods for the treatment of disorders that are mediated by kinases and HSP90.